Young TIL
- Generic Name
- Young TIL
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Phase 2
Recruiting
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 170
- Registration Number
- NCT02621021
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Advanced Non-Small Cell Lung CancerAdvanced NSCLCSquamous Cell CarcinomaAdenosquamous CarcinomaAdenocarcinoma
- Interventions
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 85
- Registration Number
- NCT02133196
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
Phase 2
Completed
- Conditions
- Metastatic MelanomaSkin Cancer
- Interventions
- Radiation: Total Body Irradiation (TBI)
- First Posted Date
- 2011-03-21
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 102
- Registration Number
- NCT01319565
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Phase 2
Recruiting
- Conditions
- Metastatic Colorectal CancerMetastatic Pancreatic CancerMetastatic Ovarian CancerMetastatic Breast CarcinomaMetastatic Endocrine Tumors/ Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2010-08-03
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 332
- Registration Number
- NCT01174121
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath